LACTEL 50:50 DL-PLG (B6010-2) is a biomedical-grade poly(DL-lactide-co-glycolide) copolymer supplied as a white to off-white particulate. The product designation identifies a 50:50 molar ratio of DL-lactide to glycolide repeat units, an acid-terminated chain architecture, and an inherent viscosity class suited to solvent-based fabrication of parenteral drug-delivery matrices. Because the DL-lactide co-monomer suppresses crystallinity, the copolymer exhibits a glass transition measured by differential scanning calorimetry at 40–50 °C on the second heating ramp at 10 °C/min, with no crystalline melting endotherm. Lot-specific values for B6010-2 should be confirmed against the manufacturer’s certificate of analysis; published data for this exact product designation is limited, and the following profile represents the product class rather than a substitute for lot release.

Because the copolymer is intended for biomedical and parenteral applications, manufacture is conducted under a quality management system consistent with ISO 13485:2016. The material is not a drug substance, but the supplier’s change control, residual monomer trending, and trace metal testing are considered part of regulatory risk assessment under ISO 10993-1:2018 and ICH Q3D(R2). The polymer is typically packaged in sealed glass or foil-laminate containers under vacuum or inert gas; each lot is accompanied by a certificate of analysis that documents the analytical release variables described below.

How Should B6010-2 Be Qualified Against Pharmacopoeial Analytical Criteria?

Release of a biomedical PLGA copolymer for parenteral applications usually requires identity, purity, residual monomer, residual solvent, elemental impurity, molecular weight, and thermal property data. For B6010-2, the appropriate test battery should include end-group titration to confirm carboxylic acid functionality, since the acid number differentiates this grade from ester-capped PLGA of identical lactide/glycolide ratio. The specification matrix below is representative for an acid-terminated 50:50 PLGA of comparable inherent viscosity; actual acceptance limits may vary by supplier and intended route of administration.

Compared with an ester-capped 50:50 PLGA, the B6010-2 carboxylic acid end group increases initial carboxylic acid density and lowers the local pH at the polymer–water interface, which accelerates ester hydrolysis autocatalytically. In phosphate-buffered saline at pH 7.4 and 37 °C, an acid-terminated 50:50 PLGA of this viscosity class typically undergoes bulk mass loss within 2–4 weeks, while an ester-capped 50:50 grade may require 3–6 weeks. The difference is measurable by acid number titration; acid-terminated grades show acid numbers above 1 mg KOH/g, whereas ester-terminated grades generally fall below 0.5 mg KOH/g. Acid number is determined by dissolving the polymer in a neutralized solvent mixture of acetone and methanol at 1:1 v/v and titrating with 0.01 M potassium hydroxide in ethanol.

Compared with poly(L-lactide-co-glycolide) grades containing crystallizable L-lactide sequences, the DL-lactide in B6010-2 prevents crystallinity, improves solubility in chloroform and dichloromethane, and lowers the percolation threshold for drug release. Compared with a 50:50 PLGA of lower inherent viscosity, B6010-2 provides higher melt viscosity and slower release; compared with a 75:25 PLGA, B6010-2 degrades faster and is preferred for release intervals under 2 months. These distinctions are not additive; end-group chemistry, molar ratio, and molecular weight interact in a nonlinear manner.

Specifying Inherent Viscosity and Residual Monomer Limits Prevents Downstream Processing Drift.

Inherent viscosity is the principal release specification governing B6010-2 processability. The standard method uses a calibrated Ubbelohde or Cannon-Fenske capillary viscometer in chloroform at 25 °C and 0.1% w/v following USP 〈621 or ISO 1628-1:2012. An acceptance interval of 0.55–0.75 dL/g corresponds to a weight-average molecular weight range of approximately 40,000–75,000 g/mol by SEC-MALS. A lot falling below 0.55 dL/g reduces the tensile integrity of cast films and increases the initial burst fraction in microparticle formulations because the lower chain length permits faster drug diffusion through the polymer-rich layer. A lot exceeding 0.75 dL/g raises solution viscosity in dichloromethane above 100 mPa·s at 20% w/v, which can complicate sterile filtration through 0.22 µm membranes and alter droplet breakup in rotor–stator homogenizers.

Residual monomer content is tightly controlled because free lactide and glycolide hydrolyze to lactic and glycolic acid during storage, lowering the pH and inducing uncontrolled chain scission. Residual lactide/glycolide totals are typically held at ≤ 1.0% by HPLC-UV. Residual solvents such as dichloromethane, chloroform, or 1,4-dioxane are monitored by headspace gas chromatography and are generally limited to ≤ 0.1% per solvent because residual solvent can plasticize the polymer and modify the effective glass transition during hot melt extrusion. Tin residuals from stannous octoate catalyst are controlled by ICP-MS; typical biomedical-grade PLGA powders report Sn below 100 ppm.

Before hot melt extrusion or solvent processing, B6010-2 requires moisture control. Because the polymer is hygroscopic and hydrolytically sensitive, exposure to ambient air above 60% RH for extended periods reduces molecular weight. Vacuum drying at 25–35 °C for 12–24 h is common; temperatures above 40 °C may cause particle agglomeration due to the low glass transition. Residual moisture should be kept below 0.5% w/w by Karl Fischer titration before extrusion.

Hot melt extrusion of B6010-2 is feasible but limited by the low glass transition. A co-rotating twin-screw extruder with an L/D ratio of 25:1 to 40:1 and barrel temperatures of 80–110 °C can process the polymer without excessive thermal degradation, provided the feed throat is purged with nitrogen and the screw speed is kept between 50–150 rpm. At barrel temperatures above 120 °C, residence times greater than 5 min may cause measurable molecular weight reduction and chain scission. In comparison, higher-lactide PLGA grades with glass transitions near 50–55 °C offer a wider extrusion window; this is a key differentiator when selecting B6010-2 versus an 85:15 PLGA for injection-molded implants.

Emulsion-Solvent Evaporation Processability and Critical Homogenization Parameters

Microsphere manufacturing with B6010-2 usually starts with dissolution in dichloromethane at 10–25% w/v. The solution is emulsified into an aqueous continuous phase containing poly(vinyl alcohol) at 0.5–2.0% w/v using a rotor–stator homogenizer at 5,000–20,000 rpm. The viscosity ratio between dispersed and continuous phases controls the Sauter mean droplet diameter. For a 0.70 dL/g inherent viscosity lot, the zero-shear viscosity of a 20% w/v dichloromethane solution is approximately 50–120 mPa·s; this range yields droplets in the 20–80 µm range with a Silverson L5M-R fine emulsor screen at 8,000–12,000 rpm, but viscous heating above 15,000 rpm can accelerate solvent evaporation and produce surface irregularity. Solvent removal is performed by stirring at 300–600 rpm under reduced pressure or by continuous extraction into an aqueous quench tank at 5–15 °C.

Bulk degradation of B6010-2 follows a four-stage sequence: water uptake, ester bond cleavage, autocatalytic acceleration, and mass loss. Differential scanning calorimetry and gel permeation chromatography during in vitro incubation in phosphate-buffered saline at pH 7.4 and 37 °C typically show a molecular weight reduction of more than 50% within 7–14 days, followed by mass loss between 2–4 weeks. As degradation products lactic acid and glycolic acid accumulate, the internal pH can drop below 3.0 in large devices, while small microspheres release acidic monomers rapidly and maintain near-neutral surface conditions.

When Terminal Carboxylic Acid Content Affects Peptide Loading and Acylation Risk in Peptide Delivery

When B6010-2 is used for peptide-loaded microspheres, the terminal carboxylic acid groups and the acidic degradation products can react with nucleophilic side chains such as lysine, histidine, or the N-terminus. Acylation of leuprolide, octreotide, or GLP-1 analogues is a documented degradation pathway in PLGA matrices. The risk is higher for acid-terminated 50:50 grades because the higher acid number and faster erosion drive the hydrated matrix pH below 5.0. Formulation countermeasures include addition of divalent cations such as Zn²⁺ at 0.5–2.0 mol% relative to peptide, inclusion of acetate or succinate buffers in the internal aqueous phase, or substitution with an ester-capped PLGA when peptide stability studies show more than 5% acylation after 4 weeks at 37 °C. Peptide identity and purity should be confirmed by reversed-phase HPLC and mass spectrometry following forced degradation protocols consistent with ICH Q1A(R2) and ICH Q3C(R8).

Terminal sterilization of B6010-2 is constrained by its low glass transition temperature; gamma irradiation at or above 25 kGy produces measurable chain scission and intrinsic viscosity loss, so ethylene oxide or aseptic filtration of bulk polymer solutions may be preferred when the regulatory dossier permits. The polymer should be stored below −20 °C under dry nitrogen or argon; repeated warming to ambient humidity above 60% RH causes hydrolytic degradation and shifts the molecular weight distribution toward lower molecular weight, altering microsphere encapsulation efficiency. For implant or microsphere development, the final polymer lot should be re-qualified for inherent viscosity and residual monomer after long-term storage, because hydrolytic drift is not always visible by macroscopic inspection.